Applications are invited from early-stage healthtech ventures with solutions to problems faced by healthcare systems globally. The call closes at midnight on 27th October 2021.
MedCity has partnered with Spex Capital to source, evaluate and fund early-stage healthtech ventures and accelerate their route to commercialisation. This exclusive partnership will support several calls for innovative companies seeking investment over the next two years.
The call is targeted at innovative health tech companies seeking Seed or Series A investment. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to be between £500k and £2 million but smaller tickets will be welcome. Successful applicants will also benefit from access to advisory teams with deep sector experience.
Leading from the MedCity side to source and evaluate viable candidates are COO Nicki Bromwich and Programme Lead Sakura Holloway. Nicki Bromwich has 30 years’ experience as a clinician in the NHS and served as Head of Commercial Development at Oxford AHSN before joining MedCity. Sakura Holloway is an IP and commercial strategist in the biotech sector with a technical background in molecular biology.
Founded in 2021 by serial healthtech entrepreneur Claudio D’Angelo, London-based Spex Capital already has a portfolio of six high-growth digital health and medtech companies. The venture firm launched with a team of 16, comprising seven investment team members, seven senior advisors and two venture partners. Founder and managing director Claudio D’Angelo leads the call from the Spex Capital side together with senior investment team member Filippo Falaschi.
MedCity is the cluster organisation for the world-leading health and life sciences sector in London and the Greater South East of England. It was set up in 2014 by the Mayor of London and the region’s Academic Health Science Centres to drive growth and investment in the sector for the health and wealth of the population.
Spex Capital is a digital health and med-tech investment management firm specialised in advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally.